Loading…
Loading…
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,707,674 shares of the company's stock, valued at approximately $33,424,000. BlackRock Inc. owned approximately 4.55% of
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,152 shares of the company's stock, valued at approximately $924,000. ADAR1 Capital Management LLC
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.